Journal Scans
Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer After D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled Trial
Capecitabine and Oxaliplatin for Gastric Cancer After Gastrectomy
YJ Bang, YW Kim, HK Yang, SH Noh, et al
Yes
20120006
2012 Jan 6
Lancet
Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer After D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled Trial
Lancet. 2012 Jan 6;[Epub Ahead of Print], YJ Bang, YW Kim, HK Yang, SH Noh, et al
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
Abstract
Background: D2 gastrectomy is recommended in US and European guidelines, and is preferred in east Asia, for patients with resectable gastric cancer. Adjuvant chemotherapy improves patient outcomes after surgery, but the benefits after a D2 resection have not been extensively investigated in large-scale trials. We investigated the effect on disease-free survival of adjuvant chemotherapy with capecitabine plus oxaliplatin after D2 gastrectomy compared with D2 gastrectomy only in patients with stage...
